<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00088972</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000377698</org_study_id>
    <secondary_id>U10CA012027</secondary_id>
    <secondary_id>S0300</secondary_id>
    <secondary_id>U10CA037429</secondary_id>
    <nct_id>NCT00088972</nct_id>
  </id_info>
  <brief_title>S0300, Celecoxib in Preventing Breast Cancer in Premenopausal Women</brief_title>
  <official_title>Randomized Placebo-Controlled Biomarker Modulation Trial Using Celecoxib in Premenopausal Women at High Risk for Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southwest Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Southwest Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the&#xD;
      development or recurrence of cancer. The use of celecoxib may be effective in preventing&#xD;
      breast cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying how well celecoxib works in preventing&#xD;
      breast cancer in premenopausal women who are at risk for developing the disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare 1-year mammographic density in premenopausal women at high risk for developing&#xD;
           breast cancer treated with celecoxib vs placebo.&#xD;
&#xD;
        -  Compare 1-year proliferation of breast epithelial cells, as measured by Ki67 staining,&#xD;
           in patients treated with these drugs.&#xD;
&#xD;
        -  Compare the expression of other biomarkers, including cyclo-oxygenase-2 (COX-2) enzyme&#xD;
           and a marker of apoptosis, in breast tissue of patients treated with these drugs.&#xD;
&#xD;
        -  Compare 1-year plasma levels of insulin-like growth factor (IGF)-1, IGF binding&#xD;
           protein-3, and prostaglandin E_2 in patients treated with these drugs.&#xD;
&#xD;
        -  Compare the toxicity of these drugs in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, placebo-controlled, double-blind, multicenter study. Patients&#xD;
      are stratified according to risk category (lobular carcinoma in situ or ductal carcinoma in&#xD;
      situ vs BRCA1/2 mutation AND any Gail risk vs Gail risk ≥1.7% but &lt; 5% vs Gail risk ≥ 5%) and&#xD;
      prior tamoxifen use (yes vs no). Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Celocoxib: Patients receive oral celecoxib twice daily.&#xD;
&#xD;
        -  Placebo: Patients receive oral placebo twice daily. In both arms, treatment continues&#xD;
           for 12 months in the absence of unacceptable toxicity or diagnosis of cancer.&#xD;
&#xD;
      Patients are followed at 1 month.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 100 patients (50 per treatment arm) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study closed due to poor accrual.&#xD;
  </why_stopped>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mammographic Density</measure>
    <time_frame>1 year</time_frame>
    <description>The primary outcome measure is change in mammographic density. The null hypothesis is that there is no difference between the arms in change in mammographic density over one year versus the alternative that the treatment arm reduces mammographic density by 10 points (percent of pixels highlighted) or more over one year compared to the change in the placebo arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ki-67 Expression</measure>
    <time_frame>1 year</time_frame>
    <description>The difference between the two arms in the percent of patients with non-zero ki-67 expression over the two time periods (baseline and 1-year).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I - Celecoxib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral celecoxib twice daily for 12 months in the absence of unacceptable toxicity or diagnosis of cancer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive oral placebo twice daily for 12 months in the absence of unacceptable toxicity or diagnosis of cancer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celecoxib</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I - Celecoxib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm II - Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  At elevated risk of developing breast cancer, as defined by 1 of the following:&#xD;
&#xD;
               -  Modified Gail risk at 5 years ≥ 1.7% or lifetime risk ≥ 20% AND Claus Model,&#xD;
                  BRCAPro Model, or Tyrer-Cuzick Model lifetime risk ≥ 20%&#xD;
&#xD;
               -  Diagnosis of lobular carcinoma in situ or ductal carcinoma in situ&#xD;
&#xD;
               -  Known deleterious mutation of BRCA1 or BRCA2&#xD;
&#xD;
          -  At least 1 breast available for imagery and biopsy&#xD;
&#xD;
          -  Has undergone a baseline mammogram with a standard density wedge within 7-14 days&#xD;
             after completion of the last menstrual period AND within 7 days before study entry&#xD;
&#xD;
               -  Mammogram normal or benign (BIRADS score 0 or 1)&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Premenopausal, defined by 1 of the following criteria:&#xD;
&#xD;
               -  Last menstrual period &lt; 6 months ago AND no prior bilateral ovariectomy AND not&#xD;
                  on estrogen replacement therapy&#xD;
&#xD;
               -  Prior hysterectomy (with ovaries still in place) AND normal follicle-stimulating&#xD;
                  hormone levels within 28 days of study entry&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Zubrod 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin &lt; 2.0 times institutional upper limit of normal (IULN)&#xD;
&#xD;
          -  SGOT or SGPT &lt; 2 times IULN&#xD;
&#xD;
          -  Alkaline phosphatase &lt; 2 times IULN&#xD;
&#xD;
          -  INR ≤ 1.5&#xD;
&#xD;
          -  PT and PTT ≤ IULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Serum creatinine &lt; 2.0 times IULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No history of myocardial infarction&#xD;
&#xD;
          -  No angina pectoris&#xD;
&#xD;
          -  No known coronary artery disease&#xD;
&#xD;
          -  No history of stroke or mini-stroke (e.g., transient ischemic attack)&#xD;
&#xD;
          -  No history of thromboembolic disease (e.g., deep vein thrombosis or pulmonary&#xD;
             embolism)&#xD;
&#xD;
          -  No uncontrolled hypertension (i.e., blood pressure &gt; 140/90 mmHg)&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No asthma after taking aspirin or other NSAIDs&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No known sensitivity to celecoxib&#xD;
&#xD;
          -  No allergy to sulfonamides&#xD;
&#xD;
          -  No urticaria or allergic-type reactions after taking aspirin or other NSAIDs&#xD;
&#xD;
          -  No extreme lactose intolerance&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated basal cell or&#xD;
             squamous cell skin cancer, carcinoma in situ of the cervix, or early bladder cancer&#xD;
             (preinvasive transitional cell carcinoma of the bladder)&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  More than 5 years since prior biologic therapy for cancer&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 5 years since prior chemotherapy for cancer&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  At least 28 days since prior tamoxifen&#xD;
&#xD;
          -  No prior systemic estrogen modifiers (SERMs) or aromatase inhibitors&#xD;
&#xD;
          -  Concurrent hormonal contraception (i.e., pills, patches, or shots) allowed provided&#xD;
             contraception was initiated prior to study entry&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to the breast to be studied&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 7 days since prior anticoagulant therapy&#xD;
&#xD;
          -  More than 1 month since prior chronic daily aspirin or nonsteroidal anti-inflammatory&#xD;
             drugs (NSAIDs) of more than 7 days duration&#xD;
&#xD;
               -  Concurrent intermittent aspirin or NSAIDs allowed (no more than 10 days per&#xD;
                  month)&#xD;
&#xD;
          -  No concurrent participation in another clinical trial for treatment or prevention of&#xD;
             cancer unless no longer receiving treatment and is in the follow-up phase&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Powel H. Brown, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Glendale Memorial Hospital Comprehensive Cancer Center</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Cancer Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131-5636</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center - Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ben Taub General Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Texas Cancer Institute at St. Luke's Episcopal Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute at Swedish Medical Center - First Hill Campus</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122-4307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Cancer Center at University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195-6043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>August 4, 2004</study_first_submitted>
  <study_first_submitted_qc>August 4, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2004</study_first_posted>
  <results_first_submitted>November 9, 2012</results_first_submitted>
  <results_first_submitted_qc>February 27, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 9, 2013</results_first_posted>
  <last_update_submitted>July 13, 2018</last_update_submitted>
  <last_update_submitted_qc>July 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>breast cancer in situ</keyword>
  <keyword>lobular breast carcinoma in situ</keyword>
  <keyword>ductal breast carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm I</title>
          <description>Patients receive oral celecoxib twice daily for 12 months in the absence of unacceptable toxicity or diagnosis of cancer.</description>
        </group>
        <group group_id="P2">
          <title>Arm II</title>
          <description>Patients receive oral placebo twice daily for 12 months in the absence of unacceptable toxicity or diagnosis of cancer.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I</title>
          <description>Patients receive oral celecoxib twice daily for 12 months in the absence of unacceptable toxicity or diagnosis of cancer.</description>
        </group>
        <group group_id="B2">
          <title>Arm II</title>
          <description>Patients receive oral placebo twice daily for 12 months in the absence of unacceptable toxicity or diagnosis of cancer.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.8" spread="3.9"/>
                    <measurement group_id="B2" value="43.3" spread="5.9"/>
                    <measurement group_id="B3" value="43.5" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mammographic Density</title>
        <description>The primary outcome measure is change in mammographic density. The null hypothesis is that there is no difference between the arms in change in mammographic density over one year versus the alternative that the treatment arm reduces mammographic density by 10 points (percent of pixels highlighted) or more over one year compared to the change in the placebo arm.</description>
        <time_frame>1 year</time_frame>
        <population>Counts represent number of patients for by arm for whom a 1 year mammographic density image was submitted. However, since the study was closed early due to poor accrual, there was insufficient accrual to evaluate study endpoints, and these images were never analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients receive oral celecoxib twice daily for 12 months in the absence of unacceptable toxicity or diagnosis of cancer.</description>
          </group>
          <group group_id="O2">
            <title>Arm II</title>
            <description>Patients receive oral placebo twice daily for 12 months in the absence of unacceptable toxicity or diagnosis of cancer.</description>
          </group>
        </group_list>
        <measure>
          <title>Mammographic Density</title>
          <description>The primary outcome measure is change in mammographic density. The null hypothesis is that there is no difference between the arms in change in mammographic density over one year versus the alternative that the treatment arm reduces mammographic density by 10 points (percent of pixels highlighted) or more over one year compared to the change in the placebo arm.</description>
          <population>Counts represent number of patients for by arm for whom a 1 year mammographic density image was submitted. However, since the study was closed early due to poor accrual, there was insufficient accrual to evaluate study endpoints, and these images were never analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ki-67 Expression</title>
        <description>The difference between the two arms in the percent of patients with non-zero ki-67 expression over the two time periods (baseline and 1-year).</description>
        <time_frame>1 year</time_frame>
        <population>Since the study was closed early due to insufficient accrual, the ki-67 data were never collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients receive oral celecoxib twice daily for 12 months in the absence of unacceptable toxicity or diagnosis of cancer.</description>
          </group>
          <group group_id="O2">
            <title>Arm II</title>
            <description>Patients receive oral placebo twice daily for 12 months in the absence of unacceptable toxicity or diagnosis of cancer.</description>
          </group>
        </group_list>
        <measure>
          <title>Ki-67 Expression</title>
          <description>The difference between the two arms in the percent of patients with non-zero ki-67 expression over the two time periods (baseline and 1-year).</description>
          <population>Since the study was closed early due to insufficient accrual, the ki-67 data were never collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm I</title>
          <description>Patients receive oral celecoxib twice daily for 12 months in the absence of unacceptable toxicity or diagnosis of cancer.</description>
        </group>
        <group group_id="E2">
          <title>Arm II</title>
          <description>Patients receive oral placebo twice daily for 12 months in the absence of unacceptable toxicity or diagnosis of cancer.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Weight gain</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pain - breast</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Statistician</name_or_title>
      <organization>SWOG</organization>
      <phone>206-667-4623</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

